USV Pvt. Ltd. has unveiled its Xenia brand series in India, leveraging the recent patent expiry of Empagliflozin. The Xenia series launches several low-cost options that can treat Type 2 Diabetes Mellitus (T2DM), heart failure, and chronic kidney disease, thus providing wider treatment options for diabetic patients numbering millions.

Key Highlights
Product Portfolio & Formulations

• Xenia 10: Monotherapy with Empagliflozin 10 mg, cost ₹125 per pack.

• Xenia 25: Monotherapy with Empagliflozin 25 mg, cost ₹163.9 per pack.

• Xenia M 12.5/500: Empagliflozin 12.5 mg + Metformin 500 mg, cost ₹140.

• Xenia M 12.5/1000 ER: Empagliflozin 12.5 mg + Metformin 1000 mg (extended-release), cost ₹165.

• Xenia ST 25: Empagliflozin 25 mg + Sitagliptin 100 mg, cost ₹220.2.

Targeted Health Conditions

• Type 2 Diabetes Mellitus (T2DM)

• Heart failure

• Chronic kidney disease

Quotes from Leaders or Officials
USV Managing Director Prashant Tewari said: "India has more than 101 million individuals with Type 2 diabetes and 136 million with prediabetes. With Xenia, we want to make modern diabetes care more accessible."With the Xenia range available at competitive prices, USV plans to reinforce its dominance in the diabetes space and open up wider access to effective and contemporary treatments. The initiative should enhance diabetes management outcomes and make therapeutic options affordable for Indian patients.